
Only human cathelicidin peptide — broad-spectrum antimicrobial against bacteria, fungi, viruses, and resistant biofilms.
Not in stock yet. Message us on WhatsApp and we'll let you know as soon as it arrives.
Ranges cited in research literature. Not a usage recommendation. For research use only.
LL-37 is the only peptide of the cathelicidin family that humans produce. It is generated by proteolytic cleavage of the precursor protein hCAP18, stored in neutrophil granules and also produced by keratinocytes and epithelial cells; the name comes from its two initial leucines and its 37 amino acids. Its expression is regulated by vitamin D, which induces the CAMP gene, one of the best-documented links between that vitamin and innate immunity.
In solution it adopts an amphipathic α-helix with a cationic face and a hydrophobic one, which lets it insert into bacterial membranes and destabilize them: it is active against Gram-positive and Gram-negative bacteria, fungi, enveloped viruses and biofilms. But its role goes beyond the antimicrobial: it acts as an immune signal through receptors such as FPR2 and P2X7, is chemotactic for neutrophils and monocytes, promotes angiogenesis and wound re-epithelialization and, in excess, is pro-inflammatory: in psoriasis it forms complexes with self-DNA that activate TLR9, and in rosacea its abnormal processing contributes to inflammation.
That dual character is the key to reading its literature. Clinical development has focused on the topical route: a Phase 2b trial with LL-37 (ropocamptide) in chronic venous leg ulcers showed healing signals in moderately sized ulcers, without reaching approval. There are no clinical data on systemic administration, and owing to its cationic nature it is cytotoxic at high concentrations. Renova distributes it for research only.
| Class | Human cathelicidin (host-defense antimicrobial peptide) |
| Sequence | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES (37 aa, amphipathic α-helix) |
| CAS | 154947-66-7 |
| Precursor / gene | hCAP18 · CAMP gene (vitamin D-inducible) |
| Activity | Broad-spectrum antimicrobial (membranes, biofilms); signaling via FPR2, P2X7; chemotaxis; angiogenesis |
| Dual face | Pro-inflammatory in excess (psoriasis: LL-37–DNA–TLR9 complexes; rosacea) |
| Clinical development | Topical: Phase 2b in venous ulcers (ropocamptide); no systemic data |
| Handling | Cationic: adsorbs to glass/plastic surfaces; cytotoxic at high concentrations; avoid freeze–thaw cycles |
Because the human genome contains a single cathelicidin gene, CAMP, which encodes the hCAP18 protein; when cleaved it releases the 37-amino-acid peptide. Other species have several cathelicidins; humans have only this one, which concentrates antimicrobial and immune functions in it.
The active form of vitamin D induces transcription of the CAMP gene in macrophages, keratinocytes and epithelial cells, increasing LL-37 production. It is one of the best-documented mechanisms by which vitamin D takes part in innate defense against infection.
In excess or when abnormally processed, yes: in psoriasis it forms complexes with self-DNA that activate TLR9 and fuel inflammation, and in rosacea its abnormal processing contributes to symptoms. At high concentrations it is also cytotoxic to human cells. That is why the literature describes it as a double-edged molecule.
Yes, by the topical route: a Phase 2b trial with LL-37 (ropocamptide) in chronic venous leg ulcers showed healing signals in moderately sized ulcers, without reaching approval. There are no trials of systemic administration; the research market's subcutaneous route lacks clinical data.
Related reading: LL-37: The Human Antimicrobial Peptide · Thymosin Alpha-1: The Thymic Immunomodulating Peptide
Informational content based on published scientific literature; it is not a recommendation for use or medical advice. Product strictly for research use (RUO), not suitable for human or veterinary consumption.
Your cart is empty